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THE EFFECT OF WEIGHT CHANGES ON HEALTH-RELATED QUALITY
OF LIFE AND WORK IMPAIRMENT IN PATIENTS WITH TYPE 2 DIABETES
Krishnarajah G1, DiBonaventura M2, Wagner S3, Gupta S4
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Consumer Health Sciences, new York, NY, USA, 
3Consumer Health Sciences International, Princeton, NJ, USA, 4Consumer Health Sciences, 
Princeton, NJ, USA
OBJECTIVES: To investigate whether patients with type-2 Diabetes Melittus (T2DM) 
who gained q5% of their bodyweight over the course of one year experienced changes 
in health-related quality of life (HRQoL) and work impairment relative to those who 
lost q5% of their bodyweight. METHODS: Data were taken from the 2006 and 2007 
National Health & Wellness Survey, an annual, cross-sectional, Internet survey of US
adults. All patients in survey with T2DM whose 2006–2007 weight gain was q5% of 
their bodyweight (n  300) were compared to those whose weight loss was q5% of 
their bodyweight (n  330) on levels of HRQoL (assessed with the SF-8 and SF-12
for 2006 and 2007, respectively) and levels of work impairment (assessed with the 
Work Productivity and Activity Impairment Questionnaire (WPAI)) in a series of 
multiple regressions, controlling for demographics, volitional weight loss (whether or
not respondents were taking steps to lose weight), and comorbidities. RESULTS: It 
was shown that weight gain was associated with signiﬁ cantly lower levels of the SF-12 
Physical Component Summary (mean score (M)  39.6 vs. M  41.5, p  0.01). Among
obese respondents, this effect was ampliﬁ ed (M  37.6 vs. M  40.3, p  0.01). No 
signiﬁ cant differences were found between T2DM patients who gained q5% of 
their weight and those who lost q5% of their weight on Mental Component Summary 
(M  48.6 vs. M  47.9, p  0.34), absenteeism (mean impairment (M)  4.6% vs. 
M  1.8%, p  0.32), presenteeism (M  18.9% vs. M  14.3%, p  0.26), total work 
impairment (M  20.1% vs. M  16.6%, p  0.46), or activity impairment (M 
33.8% vs. M  31.4%, p  0.22), though most effects were in the expected direction.
CONCLUSIONS: T2DM patients who gained weight, especially for obese individuals, 
reported signiﬁ cantly lower levels of HRQoL relative to those who lost weight. Treat-
ments that avoid weight gain and/or promote weight loss could have a beneﬁ cial
impact beyond HgbA1c for T2DM patients.
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DEVELOPMENT OF A VALUATION FUNCTION FOR A DIABETES-
SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH BASED ON THE
MULTI-ATTRIBUTE UTILITY THEORY
Sundaram M1, Smith MJ2, Revicki D3, Miller LA4, Madhavan SS2
1QualityMetric Incorporated, Lincoln, RI, USA, 2West Virginia University, Morgantown, WV, 
USA, 3United BioSource Corporation, Bethesda, MD, USA, 4University of Texas M.D. 
Anderson Cancer Center, Houston, TX, USA
OBJECTIVES: The Diabetes Utility Index (DUI) is a brief, self-administered diabetes-
speciﬁ c PBMH. We describe the development of the valuation function for the DUI 
and report its validity. METHODS: MAUT identiﬁ ed 20 of 768 DUI health states 
(anchor states, single-attribute level states, and marker states) for which preferences 
were then elicited via Visual Analog Scale and Standard Gamble (SG) tasks during 
personal interviews of individuals with diabetes recruited from primary care and com-
munity settings around Morgantown, WV. A valuation function calculating utilities 
for all DUI health states and attribute-level utilities was developed. A DUI validation 
survey was mailed in collaboration with the West Virginia University Diabetes Insti-
tute. Clinical data (ICD-9 codes and A1C values) and other self-reported data were 
merged with function-derived DUI utilities. RESULTS: Employing MAUT, a DUI valu-
ation function between 1.00  Perfect Health and 0.00  the all worse “Pits” state 
(adjusted to yield utilities between 1.00  Perfect Health and 0.00  Dead) was devel-
oped from data on 100 interviewees. A total of 396 persons with diabetes completed 
the validation survey (33% response). The DUI valuation function-derived utilities
compared favorably to cardinal SG utilities obtained directly on three DUI health 
states, but slightly underestimated SG utilities for mild and moderate health states 
(mean absolute difference  0.05). There was a small correlation between DUI utilities
and average A1C values (r  0.30, p  0.001). Respondents with two or more com-
plications had lower DUI utilities than those with none (p  0.001) or one complica-
tion (p  0.015). Insulin users had lower DUI utilities compared to non-users (p 
0.001), and those with A1C under 7 had higher DUI utilities than those with A1C of 
7 or greater (p  0.001). CONCLUSIONS: These results provide initial evidence of 
the DUIs feasibility and validity. Further research will demonstrate the generalizability
of these ﬁ ndings, show the responsiveness of the DUI, and report the clinical mean-
ingfulness of DUI change scores.
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THE IMPACT OF FREQUENCY AND SEVERITY OF SELF-REPORTED
HYPOGLYCEMIA ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2
DIABETES MELLITUS TREATED WITH ORAL ANTI-HYPERGLYCEMIC
AGENTS
Marrett E, Zhang Q, Radican L
Merck & Co., Inc., Whitehouse Station, NJ, USA
OBJECTIVES: Hypoglycemia is a side-effect of treatment with oral anti-hyperglycemic
agents (OAHAs), especially sulfonylureas (SU). This study assessed the impact of 
self-reported hypoglycemia on health-related quality of life (HRQoL) among patients
with type-2 diabetes mellitus (T2DM), treated with OAHAs. METHODS: A cross-
sectional, internet-based study was conducted among 2008 participants from the US 
National Health and Wellness Survey 2007. Patients with self-reported T2DM treated
with OAHAs only were included. For each level of self-reported hypoglycemic severity
(mild, moderate, severe), frequency (1 to 2 episodes, 3 to 6 episodes, or  than once 
per month) data for six months prior to survey were collected. Very severe hypogly-
cemia (medical assistance required) was recorded as either one episode or  to two 
episodes. Utility was measured using the EQ-5D, and fear of hypoglycemia using the
Worry subscale of the Hypoglycemia Fear Survey II (HFS). RESULTS: Mean age was 
58 (o11) years, 43% were female, and 72.2% reported HbA1c goal attainment (7%). 
The proportions of patients on SU monotherapy, SU combination therapy, and other 
treatment regimens were 10.7%, 39.7%, and 49.6%, respectively. Hypoglycemic epi-
sodes were reported by 61.6% of patients (45.6% mild, 37.4% moderate, 13.2% 
severe and 3.8% very severe). After adjusting for age, gender, weight gain, microvas-
cular and macrovascular complications, the utility scores decreased by increasing 
severity and frequency of hypoglycemic episodes (with reference  no hypoglycemia), 
i.e., 0.008, 0.013, 0.015 for mild respectively, 0.046, 0.061, 0.11 for moderate, 0.089,
0.16, 0.27 for severe, and 0.17, 0.27 for very severe, whereas HFS scores increased, 
4.6, 5.5, 7.8 for mild, 11.4, 15.2, 13.8 for moderate, 15.5, 20.1, 25.5 for severe, and 
25.6, 26.6 for very severe. CONCLUSIONS: Self-reported hypoglycemia was experi-
enced by over half of the patients on OAHAs and was associated with reduced quality
of life. The magnitude of the reduction increased with frequency and severity of 
hypoglycemic episodes.
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THE HANDLING OF GLUCOSE MONITORING AND INSULIN
TREATMENT (HAGLUMIT) QUESTIONNAIRE CAPTURES HANDLING 
DIFFERENCES BETWEEN DIFFERENT SITUATIONS AND SYSTEMS FOR
MONITORING BLOOD GLUCOSE IN DIABETES
Mast O1, Schmidt U2
1Roche Diagnostics, Ltd, Mannheim, Germany, 2Roche Diagnostics, Ltd, Mannheim, Baden-
Württember, Germany
OBJECTIVES: Evaluate difﬁ culties in handling Self Monitoring of Blood Glucose
(SMBG) from a patient’s perspective under normal and stressed conditions, using a 
new strip-free SMBG system. METHODS: The newly developed HaGluMIT question-
naire captures patient-reported ease of performing 9 typical steps in the SMBG process 
(7-point scale: 1 (very easy) to 7 (very difﬁ cult)). Fifty insulin treated diabetes patients
participating in a 2-week product evaluation study used the new Accu-Chek Mobile 
system in parallel to their current SMBG systems. They were asked to voluntarily ﬁ ll
out HaGluMIT at the beginning (current system) and the end (new system). RESULTS:
Thirty-six subjects completed both questionnaires and were eligible for comparative 
analysis (1 missing pre-evaluation and 13 missing post-evaluations). Mean SMBG
duration was 14 years with currently 5.7 tests per day. Twenty-three subjects were 
using an insulin pump. Data logging (2.68) was perceived to be most difﬁ cult to handle
under normal conditions followed by teststrip vials (2.44), lancets (2.26), carrycase
(2.10), teststrips (2.06), meter (1.97), blood application (1.94), lancet device (1.91) 
and insulin application (1.75). Under stressed conditions scores increased an average
of 0.68 points. Post-evaluations demonstrated statistically signiﬁ cant improvements 
for lancets, blood application and data logging under normal and stressed conditions 
in favor of the new system. The impact of stress was lower (average increase: 0.59 
points). CONCLUSIONS: A number of patient reported handling problems in per-
forming SMBG are reported in former research. This might result in skipping tests or 
making decisions based on inaccurate measures. Data logging is perceived to be most 
difﬁ cult to handle, followed by lancets, teststrips/vials and carrycase. HaGluMIT 
captures changes in handling difﬁ culty. Stress (e.g. from public attention, time pressure 
or hypoglycemic states) increases the difﬁ culty of handling. An integrated SMBG 
system without single strips and lancets signiﬁ cantly improved handling difﬁ culties
under normal and stressed conditions.
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PERCEPTION VERSUS REALITY – CATEGORISATION OF PATIENT 
WEIGHT BY TYPE 2 DIABETES (T2DM) PATIENTS AND THEIR
PHYSICIANS IN THE US AND EUROPE
Stahl E1, Benford M2, Leith A2, Colclough HA3, Watmough A2, Grandy S4
1AstraZeneca R&D Lund, Lund, Sweden, 2Adelphi Group Products, Bollington, Cheshire, UK, 
3Adelphi Group Products, Chesire, UK, 4AstraZeneca, Wilmington, DE, USA
OBJECTIVES: The objective was to understand how type-2 diabetes mellitus (T2DM) 
patients and their physicians perceive weight in relation to the objective measure
of body mass index (BMI). METHODS: Analysis was performed using data from 
the Adelphi Diabetes Disease Speciﬁ c Programme (DSP), a large cross-sectional 
study of clinical and treatment practice. Physicians (diabetologists and primary care 
practitioners) provided clinical assessment and information on T2DM patients. All
physicians and consenting patients were required, separately, to categorise patient 
weight as: normal, overweight, severely overweight/obese, severely obese. Physicians
also provided height and weight for patients but were not required to calculate BMI. 
Physician and patient estimates were subsequently compared with calculated BMI 
for each patient. RESULTS: A total of 132 (US) and 511 (5 EU countries) physicians
participated. Physicians categorised the weight of 928 (US) and 3969 (EU) T2DM 
patients for whom BMI was calculated. Equivalent matched numbers of patients 
categorising their weight was 626 (US) and 2013 (EU). Patient mean age was 62 years;
duration of T2DM 6 years; 51% were male; 55% in US and 33% in EU were 
obese (BMI / 30). Across all weights, some patients’ weight category was underes-
timated by their physicians (US 38% underestimated vs. 54% correct; EU 21% vs. 
69%). T2DM patients were more likely to underestimate their weight (US 60% 
underestimated vs. 37% correct, EU 43% vs. 51%). Discrepancies in weight estima-
tion were greatest for countries where overall mean BMI was 30 (US, UK) and least 
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where mean BMI was lowest (Italy). CONCLUSIONS: Weight control is an important 
aspect of management of T2DM. This requires accurate assessment and agreement of 
patient weight and BMI levels by treating physicians and their patients. Accurate
risk stratiﬁ cation based on weight and BMI may help improve effective communica-
tions and disease management decisions between T2DM patients and their treating
physicians.
PDB43
PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH
TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO 
EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH
Schmidt WE1, Christiansen JS2, Hammer M3, Zychma MJ4, Buse J5
1Ruhr University, Bochum, Germany, 2Århus University Hospital, Århus, Denmark, 3Novo
Nordisk A/S, Bagsværd, Denmark, 4Novo Nordisk A/S, Bagsvaerd, Denmark, 5University of 
North Carolina School of Medicine, Chapel Hill, NC, USA
OBJECTIVES: New treatments for T2D are needed to improve glycemic control,
reduce side-effects, and improve patient satisfaction. Liraglutide is an OD human
GLP-1 analog that has beneﬁ ts as monotherapy, or in combination with OADs. 
METHODS: The Liraglutide Effect and Action in Diabetes 6 (LEAD-6) trial was an 
open-label trial comparing liraglutide to exenatide as add-on to OADs. Adults with 
T2D on metformin and/or sulfonylurea and A1C 7–11% were randomized to liraglu-
tide 1.8 mg OD or exenatide 10 Mg BD for 26 weeks. This was followed by a 14-week
extension phase, in which all patients received liraglutide 1.8mg OD. RESULTS:
During weeks 0–26, A1C reductions were signiﬁ cantly greater and the incidence of 
hypoglycemia was signiﬁ cantly lower in the liraglutide-treated group. Patient Reported 
Outcomes were measured in 379 patients using Diabetes Treatment Satisfaction Ques-
tionnaire status (DTSQs) at week 0, 26, 34 and 40 and DTSQ change (DTSQc) at
week 26 and 34. The overall treatment satisfaction was highest with liraglutide (p 
0.0001); DTSQs score increased from 27.4 at baseline to 32.1 at week 26 compared 
to exenatide (increase from 27.6 to 29.3). All items on DTSQs except ‘understanding’ 
(ie ‘current treatment’, ‘convenience’, ‘ﬂ exibility’, ‘recommend’, ‘continue’) improved
signiﬁ cantly more with liraglutide than exenatide. The proportion of ‘satisﬁ ed’ patients 
(deﬁ ned as DTSQc  6) was 94% in liraglutide, 86% with exenatide (p  0.0176). 
Patients perceived a greater reduction in hypoglycemia at week 26 with liraglutide 
(DTSQc 0.9) than with exenatide (0.4; p  0.0193) and a greater reduction in per-
ceived hyperglycemia (1.0, 0.3, respectively; p  0.0007). During the extension 
phase, when all patients received liraglutide, DTSQs scores remained stable in patients 
who continued on liraglutide and had increased signiﬁ cantly (p  0.0131) at week 40 
in those who switched from exenatide to liraglutide at week 26. CONCLUSIONS:
These results demonstrate signiﬁ cant improvements in patients’ treatment satisfaction 
with liraglutide compared to exenatide.
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EFFECTS OF INSULIN THERAPY ON THE DIABETES SYMPTOM
CHECKLIST-REVISED (DSC-R): DATA FROM A LARGE INSULIN
CLINICAL TRIAL
Nelson L1, McLeod LD1, Lee LJ2, Hill C1, Sweeney C1, Sun P3, Fahrbach J2, Martin S2, 
Weinstock RS4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, 
IN, USA, 3Kailo Research Group, Indianapolis, IN, USA, 4SUNY Upstate Medical University 
and the Department of Veterans Affairs Medical Center, Syracuse, NY, USA
OBJECTIVES: To examine the impact of insulin initiation on the DSC-R in patients 
with type 2 diabetes (T2D). METHODS: We administered the DSC-R to T2D patients 
enrolled in a large insulin clinical trial (acronym: DURABLE) at baseline prior to 
starting insulin and at six months post-insulin initiation. The trial compared the efﬁ -
cacy and safety of insulin initiation with lispro mix 75/25 versus insulin glargine. The
DSC-R is a T2D-speciﬁ c measure that assesses the occurrence and the perceived burden 
of the following eight T2D-related symptoms: hypoglycemic, hyperglycemic, cardio-
vascular, neuropathic/pain, neuropathic/sensory, psychological/fatigue, psychological/
cognitive, and ophthalmologic/vision. Summary score for each domain ranged from
0–100 with higher scores indicating greater symptom burden. We compared change
in mean score (baseline to six months) for two insulin arms combined together. Effect
size (ES; cohen’s d) and analysis of covariance were used to examine the extent and 
signiﬁ cance of change. Effect sizes of 0.2, 0.5, and 0.8 represent small, medium, and 
large degrees of change, respectively. RESULTS: A total of 576 patients completed the
DSC-R at both time points. The mean age, duration of diabetes, A1c, and percent
female at baseline were 57.0 years, 9.6 years, 8.9%, and 41%, respectively. Baseline 
mean scores ranged from 24.2 (cardiovascular and neuropathic/pain) to 45.9 (psycho-
logical/fatigue). The mean scores at 6 months ranged from 22.6 (ophthalmologic/
vision) to 40.7 (psychological/fatigue). Absolute changes in the mean domain score 
ranged from 0.6 (neuropathic/sensory) [p  0.45; ES  0.02] to 9.8 (hyperglycemic) 
[p  0.0001; ES  0.38; small to medium effect]. Other domains with ES q0.20 were 
psychological/fatigue and psychological/cognitive. CONCLUSIONS: Initiation of 
insulin therapy was associated with a small to moderate improvement in hyperglyce-
mic symptoms domain. Small effects were also observed in psychological/fatigue and
psychological/cognitive domains.
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SATISFACTION WITH DIABETES TREATMENTS: IMPACTS ON PATIENT 
HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY
Pollack M1, Waterman F2, Bolge SC3, Williams S4
1AstraZeneca, LP, Wilmington, DE, USA, 2Consumer Health Sciences, New York, NY, USA, 
3Consumer Health Sciences International, Princeton, NJ, USA, 4AstraZeneca, Wilmington, 
DE, USA
OBJECTIVES: Diabetes is a debilitating and common illness that can lead to signiﬁ -
cant disability. Key patient-reported outcomes are important as they can inﬂ uence
productivity and patient health-related quality of life (HRQL). The objectives of the 
current research were to: (1) assess the current level of treatment satisfaction within
existing oral anti-diabetics (OADs) and (2) determine the association between treat-
ment satisfaction and productivity and HRQL. METHODS: The current study design 
was a cross-sectional web-based survey of adults diagnosed with type 2 diabetes mel-
litus (T2DM) using OADs, but not insulin. Treatment satisfaction was assessed using
the Diabetes Medication Satisfaction questionnaire (DiabMedSat). HRQL was exam-
ined with the EQ-5D instrument. The Work Productivity and Activity Impairment 
(WPAI) and Diabetes Productivity Measure (DPM) questionnaires were used to assess 
productivity. Pearson’s correlations and linear regression models were used to assess 
strength and direction in association. RESULTS: Of 2,074 survey respondents, 53%
were men and mean age was 60 years (SD  10.83). 64% of respondents report being 
very/extremely satisﬁ ed with their diabetes treatments. Total DiabMedSat score was 
79.5; higher scores were reported with the burden subscale (89.5) versus the efﬁ cacy 
and symptom (i.e. tolerability) sub-scales (69.8 and 69.5). There was a direct correla-
tion between overall treatment satisfaction and higher EQ-5D scores (r2  0.401, 
p  0.001), and increased work and life productivity (DPM: r2  0.595 and r2  0.640, 
p  0.001). Similar correlation results were observed with WPAI. After controlling
for patient demographics, treatment satisfaction has greater effects on presenteeism
(impairment while working) (WPAI: 0.472, 95% CI: 0.611 to –0.333, p  0.001) 
than absenteeism (missed work time) (WPAI: 0.057, 95% CI: 0.157 to 0.043, p 
0.263). CONCLUSIONS: Among T2DM patients, there is a high level of satisfaction
with OAD therapies, though improvements could be made in efﬁ cacy and tolerability. 
Increases in treatment satisfaction can have a direct improvement on productivity and 
health-related quality of life.
PDB46
CONTRIBUTIONS OF AND RELATIONSHIP BETWEEN EXPECTATIONS 
ABOUT AND EXPERIENCES WITH INSULIN THERAPY TO TREATMENT
SATISFACTION IN INSULIN-NAÏVE PATIENTS WITH TYPE-2 DIABETES
Naegeli AN, Hayes RP
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To assess the relationship between patients’ expectations about and 
experiences with insulin therapy, and how they contribute to overall treatment satisfac-
tion. METHODS: The Expectations about Insulin Therapy (EAITQ) and the Experi-
ence with Insulin Therapy Questionnaires (EWITQ) were administered at baseline and 
endpoint, respectively, to insulin-naïve patients with type-2 diabetes in a randomized 
controlled trial comparing treatment algorithms for an inhaled insulin. Pearson 
correlation coefﬁ cients were calculated between EAITQ and EWITQ scores and 
patient characteristics and patient reported outcomes measures. Wilcoxon Signed 
Rank test was used to compare EAITQ and EWITQ item score distributions. Differ-
ences between EAITQ and EWITQ scores were calculated to categorize patients 
into three groups according to the extent to which their expectations about insulin
therapy were met by experiences (i.e., not met, met, and exceeded). Oneway analysis
of variance with Scheffe post-hoc tests was performed to detect differences in treatment
satisfaction scores among the three groups. RESULTS: EAITQ and EWITQ data
were available for 240 patients (male: 61% male, age: 58 (mean) years old, diabetes
duration: 10 years, HbA1c: 8.4%). More positive expectations were signiﬁ cantly
associated with greater self-efﬁ cacy (p  0.01); more positive experiences were signiﬁ -
cantly associated with shorter diabetes duration, less symptom distress and greater 
well-being, self-efﬁ cacy, and treatment satisfaction (p  0.01). Overall, patients’ 
experiences with insulin therapy were signiﬁ cantly more positive than their 
expectations, with 58% of patients’ experiences exceeding expectations, 29% experi-
ences met by expectations, and 13% experiences less than expectations. Post-hoc
tests indicated that diabetes treatment satisfaction scores were signiﬁ cantly different
among the three groups with higher scores associated with the exceeding of exp-
ectations by experiences. CONCLUSIONS: Expectations may not independently 
impact treatment satisfaction, but their relationship with experiences signiﬁ cantly
contributes to treatment satisfaction. The EAITQ and EWITQ may be useful tools
for clinicians in identifying differences in expectations and experiences concerning
insulin therapy.
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THE ASSOCIATION BETWEEN PATIENT-REPORTED DIABETES
SYMPTOMS AND TOLERABILITY ISSUES OF ORAL ANTIDIABETIC 
AGENTS ON WORK AND LIFE PRODUCTIVITY
Pollack M1, Bolge SC2, Williams S1, Waterman F3
1AstraZeneca, Wilmington, DE, USA, 2Consumer Health Sciences International, Princeton, NJ, 
USA, 3Consumer Health Sciences, New York, NY, USA
OBJECTIVES: Diabetes symptoms and tolerability issues of existing treatments may 
affect work productivity, contributing to the overall burden of type-2 diabetes mellitus 
(T2DM). Objectives were to document the frequency of diabetes symptoms and 
tolerability issues among existing oral antidiabetic drugs (OAD) and determine their
